Clene Q3 2026 earnings

CLNN · 2026-11-04 08:35 BMO ET · 8-K on SEC · 10-Q on SEC

Net income turned positive to $3.9 million, supported by a $10.3 million swing in fair value of warrant liabilities.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$56+273%-38%Ex. 99.1, income statement
EPS (GAAP)$0.30N/AN/AEx. 99.1, income statement
Net income$3.9N/AN/AEx. 99.1, income statement
Adj. EBITDA$1.0N/AN/AEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Product revenue$43N/A77%—
Royalty revenue$13N/A23%—

Margins and costs

  • Gross margin 28.6% (prior 0%, change +28.6 pp)
  • Operating expenses $6.4 million (+13%)
  • One-offs in the quarter Change in fair value of common stock warrant liabilities: $7.5 million; Change in fair value of derivative liabilities: $3.4 million; Issuance costs for common stock warrant liabilities: $0.4 million; Loss on initial issuance of equity: $4.6 million
  • Effective tax rate N/A
  • Non-GAAP bridge Net income is adjusted for change in fair value of warrant liabilities ($7.5M) and derivative liabilities ($3.4M) to arrive at Adj. EBITDA of $1.0M.

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$9.9$9.7$5.2+2%
Research and development expenses$4.4$3.5$3.5+27%
General and administrative expenses$1.9$1.9$2.2-10%

Guidance

not stated in the 8-K

What drove it

  • Revenue story Product revenue declined 42% QoQ to $43 million; total revenue declined 38% QoQ to $56 million.
  • EPS story Positive net income of $3.9 million ($0.30 EPS) driven by a $13.3 million swing in total other income (expense), net, primarily from fair value changes in warrant and derivative liabilities.
  • One-off check Change in fair value of common stock warrant liabilities: $7.5 million; Change in fair value of derivative liabilities: $3.4 million; Issuance costs for common stock warrant liabilities: $0.4 million; Loss on initial issuance of equity: $4.6 million.

The good

  • Net income turned positive to $3.9 million
  • Cash and cash equivalents increased to $9.9 million

The bad

  • Product revenue declined 42% QoQ to $43 million
  • R&D expenses increased 27% YoY to $4.4 million

The ugly

  • none

Open questions

  • What is the specific magnitude of the fair value changes in warrant and derivative liabilities?
  • What is the specific amount of proceeds expected from the exercise of warrants?
Full release

Clene (CLNN) earnings release, November 4, 2026

Clene Inc. (CLNN) · Form 8-K, Item 2.02 · Filed · SEC filing

CLENE REPORTS

Third

QUARTER

2026

FINANCIAL RESULTS

AND RECENT OPERATING HIGHLIGHTS

SALT LAKE CITY, November 4,

2026

-- Clene Inc. (Nasdaq: CLNN), a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced its third quarter 2026 financial results and provided updates on its CNM-Au8 programs.

“Clene’s submission of the NDA for CNM-Au8 is a pivotal achievement for the company and, more importantly, a meaningful step toward bringing new treatment options to people living with ALS,” said Rob Etherington, President and CEO of Clene. “People living with ALS urgently need additional treatment options, and we appreciate the FDA’s constructive engagement throughout this process. We look forward to working closely with the Agency during its pending review. We believe CNM-Au8 has the capacity to restore and protect neuronal health and function and improve survival.”

Third

Quarter

2026 and Recent Operating Highlights

CNM-Au8 for the treatment of ALS

In October, Clene submitted an NDA to the FDA seeking accelerated approval of CNM-Au8 for ALS. The NDA is supported by NfL biomarker and clinical data from the Phase 2 HEALEY ALS Platform Trial and its open-label extension, the Phase 2 RESCUE-ALS Trial, and the NIH-sponsored Expanded Access Protocol for CNM-Au8.

Clene plans to randomize the first participants for the Phase 3 RESTORE-ALS trial in the second quarter of 2027. The trial will evaluate the effect of CNM-Au8 on survival (primary endpoint) and time to ALS clinical worsening events (secondary efficacy endpoint).

Corporate Update

In September, the Company closed a $4.0 million registered direct offering of common stock to existing stockholders, including insiders, priced at $3.28 per share. The offering was led by Clene’s Chairman, David Matlin, with founding investor Kensington Capital Holdings, Clene’s CEO and other existing stockholders.

The Company expects the proceeds from the offering to fund operations through mid-first quarter 2027. Subject to FDA acceptance of the NDA for review, the Company could receive $6.7 million to $7.8 million in proceeds from common stock warrants issued in its January 2026 financing.

Third

Quarter

2026

Financial Results

Clene’s cash and cash equivalents totaled

$9.9 million as of

September 30, 2026, compared to

$5.2 million as of

December 31, 2025.

Net cash used in operating activities was

$11.7 million for the nine months ended September 30, 2026, compared to

$13.7 million for the same period in

2025. Clene expects that its resources as of

September 30, 2026, will provide operating runway through mid-first quarter 2027.

Research and development expenses were

$4.4 million for the quarter ended

September 30, 2026, compared to

$3.5 million for the same period in

2025, an increase of approximately 27%. The increase was primarily due to higher regulatory expenses for the NDA submission, as well as higher manufacturing and personnel expenses. Personnel expenses rose due to non-executive salary increases and the reinstatement of previously reduced executive compensation. Additionally, lower grant revenue was recorded in 2026, which is recorded as a reduction to research and development expense. These increases were partially offset by lower clinical expenses related to Clene’s lead drug candidate, CNM-Au8, for both its ALS and MS clinical programs and lower stock-based compensation expense.

General and administrative expenses were

$1.9 million for the quarter ended

September 30, 2026, compared to

$2.2 million for the same period in

2025, a decrease of approximately 10%. The decrease was primarily due to lower insurance costs, legal fees, finance and accounting fees and stock-based compensation expenses, partially offset by higher personnel expenses, as described above.

Total other income, net, was

$10.3 million for the quarter ended

September 30, 2026, compared to total other expense, net, of

$3.1 million for the same period in

2025. The change was primarily due to a change in fair value of common stock warrant liabilities and derivative liabilities.

Clene reported net income of

$3.9 million, or

$0.30 per basic share and

$0.05 per diluted share, for the quarter ended

September 30, 2026, compared to a net loss of

$8.8 million, or

$0.85 per basic and diluted share, for the same period in

2025.

About Clene

Clene Inc. (Nasdaq: CLNN), along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on

X

(formerly

Twitter) and

LinkedIn.

About CNM-Au8®

CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc.

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited) (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue:
Product revenue43$—11865
Royalty revenue13154358
Total revenue5615161123
Operating expenses:
Cost of revenue165220
Research and development4,4473,5138,2478,508
General and administrative1,9402,1505,6177,183
Total operating expenses6,4035,66313,91615,711
Loss from operations-6,347-5,648-13,755-15,588
Other income (expense), net:
Interest income5040152183
Interest expense-665-649-2,151-1,936
Issuance costs for common stock warrant liabilities-393
Loss on initial issuance of equity-4,582
Change in fair value of common stock warrant liabilities7,493-1,7282,301267
Change in fair value of derivative liabilities3,368-797748-89
Research and development tax credits and unrestricted grants16580216
Total other income (expense), net10,262-3,129-3,845-1,359
Net income (loss) before income taxes3,915-8,777-17,600-16,947
Net income (loss)3,915-8,777-17,600-16,947
Other comprehensive income:
Foreign currency translation adjustments1915579
Total other comprehensive income1915579
Comprehensive income (loss)3,934-8,776-17,545-16,868
Net income (loss) per share – basic and diluted
Basic0.3-0.85-1.42-1.77
Diluted0.05-0.85-1.42-1.77
Weighted average common shares used to compute basic and diluted net income (loss) per share
Basic13,079,59910,284,67412,374,0969,549,661
Diluted14,668,74210,284,67412,374,0969,549,661

Balance Sheet

September 30, — (Unaudited) (in thousands)

September 30, – 2026December 31, – 2025
Current assets:
Cash and cash equivalents9,8875,189
Accounts receivable43
Inventory4137
Prepaid expenses and other current assets4,5233,751
Total current assets14,4948,977
Restricted cash5858
Operating lease right-of-use assets2,5873,073
Property and equipment, net5,0186,023
TOTAL ASSETS22,15718,131
Current liabilities:
Accounts payable862892
Accrued liabilities2,5105,002
Operating lease obligations, current portion788808
Notes payable, current portion4,9741,696
Convertible notes payable, current portion7,9802,378
Total current liabilities17,11410,776
Operating lease obligations, net of current portion2,6033,250
Notes payable, net of current portion9643,741
Convertible notes payable, net of current portion5,2959,800
Common stock warrant liabilities8,6445,063
Derivative liabilities2,3453,093
TOTAL LIABILITIES36,96535,723
Stockholders’ deficit:
Common stock, $0.0001 par value: 600,000,000 shares authorized; 14,213,981 and 10,849,974 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively11
Additional paid-in capital310,860290,531
Accumulated deficit-325,896-308,296
Accumulated other comprehensive income227172
TOTAL STOCKHOLDERS’ DEFICIT-14,808-17,592
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT22,15718,131

Cash Flow

From the 10-Q · Nine Months Ended September 30, — Supplemental Cash Flow Information (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating cash flows from operating leases-980-1,004

Forward-Looking Statements... (truncated)tion 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Clene’s forward-looking statements include, but are not limited to, statements regarding the FDA’s review and potential acceptance of the Company’s NDA for CNM-Au8, the potential for accelerated approval of CNM-Au8, the timing of the Company’s confirmatory Phase 3 RESTORE-ALS trial, the sufficiency of the Company’s cash runway, the potential receipt of proceeds from the exercise of warrants, and the potential benefits of CNM-Au8. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Investor Contact

: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; 617-283-2856

Media Contact

: Caroline Wagner, FTP;

CWagner@ftpadvocacy.com; 267-294-6563

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.